Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Mar 15;113(11):E1419-20.
doi: 10.1073/pnas.1522052113. Epub 2016 Feb 25.

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report

Affiliations
Comment

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report

Vivek Subbiah et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
CT scan of the chest showing nodule in the right lateral chest wall: (A) before ceritinib; (B) 8 wk after ceritinib. MRI brain scan showing cerebellar metastasis: (C) before ceritinib; (D) 8 wk after ceritinib.

Comment on

References

    1. Davare MA, et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci USA. 2015;112(39):E5381–E5390. - PMC - PubMed
    1. Shaw AT, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971. - PMC - PubMed
    1. Shen L, Ji HF. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(26):2537. - PubMed
    1. Shaw AT, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–1197. - PMC - PubMed
    1. Kang BP, et al. The signature program: Bringing the protocol to the patient. Clin Pharmacol Ther. 2015;98(2):124–126. - PMC - PubMed

MeSH terms

LinkOut - more resources